1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. LAURUS LABS LTD.
Laurus Labs Ltd.
NSE: LAURUSLABS | BSE: 540222

Laurus Labs Live Share Price Today, Share Analysis and Chart

Expensive Star
BasketIn 1 Starfolio Basket
aboutLaurus Labs Ltd. is a research-driven, integrated pharmaceutical company with a leadership position in the global generic market, particularly in high-potency Active Pharmaceutical Ingredients (APIs) and antiretroviral (ARV) therapies. The company op... Read More
US FDA InspectionsANDA Approvals
Ask AI about Laurus Labs
2405.50161.50(7.20%)

New 52W High today

8.5M
NSE+BSE Volume

High volume+gain today

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Dividend
Laurus Labs has an upcoming dividend of ₹1.000 per share due on 06 Nov 2026 See details
Loading...
- / 100
- / 100
75.7 / 100
Expensive StarThese stocks are bullish, strong in quality and technicals, but expensive in valuation. Investors need to be cautiousView SimilarEmbed DVM
Analyst Price Target
-

49

S

7

W

3

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

18Positive5Negative

Pass in checklist78.3%

045
55
100

PE Valuation Check

Right Now
Overvalued
-7.4%
1 Year Forward
Undervalued
10.6%
INSIGHTLaurus Labs is overvalued at current PE, but undervalued on future earnings estimates

Laurus Labs Stock Price Analysis

Day Price Range

7.2% 1 Day return
2405.5 (LTP)
2,206.12,405.5
LowHigh

Week Price Range

22.1% 1 Week return
2405.5 (LTP)
1,951.62,405.5
LowHigh

Month Price Range

21.6% 1 Month return
2405.5 (LTP)
1,933.52,405.5
LowHigh

52 Week Price Range

147.9% 1 Year return
2405.5 (LTP)
9182,405.5
LowHigh
View full Price History/Seasonality

Laurus Labs Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Laurus Labs's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
16.5
AVG. ESTIMATE
30.4
LOW ESTIMATE
29
HIGH ESTIMATE
33.3
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 84.9% in FY27

Consensus Recommendation

15 ANALYST Recommendations
HOLD

The consensus recommendation from 15 analysts for Laurus Labs is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Laurus Labs Technical Analysis

Laurus Labs EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day2235.3
10 Day2157.8
12 Day2140.1
20 Day2093.3
26 Day2068.0
50 Day1979.5
100 Day1807.7
200 Day1553.0

Laurus Labs Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202631.9%
Week37.7%
Month43.8%

Laurus Labs Active Candlesticks

Closing Marubozu Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Laurus Labs Resistance and Support

2339.03
Pivot
First Resistance2472.0
Second Resistance2538.4
Third Resistance2671.4
First Support2272.6
Second Support2139.6
Third Support2073.2
Day RSI78.7
Day MACD72.1
Day MFI75.1
Day MACD Signal Line43.4

Laurus Labs Beta

1 Month1.0
1 Year0.8
3 Month0.7
3 Year1.0

Laurus Labs Price Change Analysis

↑21.6%
Over 1 Month
LowHigh
1933.52405.5
↑35.0%
Over 3 Months
LowHigh
1769.42405.5
↑117.5%
Over 6 Months
LowHigh
10802405.5
↑147.9%
Over 1 Year
LowHigh
918.02405.5
All Technicals →

Laurus Labs Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
M/S. Nsn Holdings (Represented By Its Managing Partner, Dr. Satyanarayana Chava)Promoter124,126,74023.0 %
New World Fund IncFii19,057,0553.5 %
Anukar Projects Private LimitedPublic17,483,6103.2 %
Mirae Asset Nifty India Manufacturing EtfDii21,700,8814.0 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Laurus Labs Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
SOCIETE GENERALEBulkSell31 Aug 20261903.842,810,437NSE
BNP PARIBAS FINANCIAL MARKETSBulkSell31 Aug 20261914.286,272,175NSE
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.BulkSell31 Aug 20261914.045,134,361NSE
BNP PARIBAS FINANCIAL MARKETSBulkPurchase31 Aug 20261860.3515,399NSE
INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD.BulkPurchase31 Aug 20261922.691,718NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell27 Jan 2025536.233,689,009NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase27 Jan 2025536.503,690,709NSE
CYBAGE SOFTWARE PRIVATE LIMITEDBlockSell14 Mar 2023305635,894NSE
ARUN VIJAY NATHANIBlockPurchase14 Mar 2023305635,894NSE
ISHARES CORE EMERGING MARKETS MAURITIUS COBlockSell14 Nov 2022455.40529,337NSE
All deals
All insider trades

Laurus Labs Corporate Actions

Laurus Labs Dividend history and yield

Laurus Labs dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Laurus Labs dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
106 Nov 2026
1INTERIM06 Nov 2026Equity Share
208 May 2026
1.2INTERIM08 May 2026Equity Share
331 Oct 2025
0.8INTERIM31 Oct 2025Equity Share
409 May 2025
0.8INTERIM09 May 2025Equity Share
506 Nov 2024
0.4INTERIM06 Nov 2024Equity Share

Laurus Labs Board Meetings

Laurus Labs past and upcoming board meetings.

#Ex-Date
PurposeNotes
129 Oct 2026
Quarterly Results & Interim Dividend-
224 Jul 2026
Quarterly Results-
330 Apr 2026
Audited Results & Interim Dividend-
423 Jan 2026
Quarterly Results-
523 Oct 2025
Quarterly Results & Interim Dividend-

Laurus Labs Stock Split

Laurus Labs stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
129 Sep 2020
10230 Sep 2020
All Corporate Actions

Laurus Labs Research Reports

Laurus Labs research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
126 Jul 2026Deven Choksey
Target
18301601.2Accumulate14.29%50.23%pdf
225 Jul 2026ICICI Direct
Target
18901601.2Buy18.04%50.23%pdf
323 Jul 2026Motilal Oswal
Target
19801601.2Buy23.66%50.23%pdf
423 Jul 2026Deven Choksey
Target
17051568.3Accumulate8.72%53.38%pdf
506 May 2026Deven Choksey
Reco
Target
12811206.5Accumulate6.17%99.38%pdf
All Reports of Laurus

Laurus Labs Corporate Filings

Laurus Labs BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please see annexed enclosure.
PDF
29 Oct 2026
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please see enclosed annexure.
PDF
29 Oct 2026
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please see enclosed annexure
PDF
29 Oct 2026
Q2FY27 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals company Laurus Labs announced Q2FY27 results Consolidated Financial Highlights: Revenue from Operations: Reached Rs 2,206.37 crore in Q2FY27, reflecting an increase of 8.89% QoQ compared to Rs 2,026.31 crore in Q1FY27 and an increase of 33.44% YoY compared to Rs 1,653.47 crore in Q2FY26. Other Income: Stood at Rs 13.01 crore in Q2FY27, rising 41.72% QoQ from Rs 9.18 crore in Q1FY27, but declining 51.74% YoY from Rs 26.96 crore in Q2FY26. Total Income: Stood at Rs 2,219.38 crore in Q2FY27, registering a QoQ growth of 9.03% from Rs 2,035.49 crore in Q1FY27 and a YoY growth of 32.07% from Rs 1,680.43 crore in Q2FY26. Profit Before Tax: Reported at Rs 591.82 crore in Q2FY27, increasing 22.95% QoQ from Rs 481.36 crore in Q1FY27 and 119.41% YoY from Rs 269.73 crore in Q2FY26. Net Profit After Taxes and Share of Net Profit/(Loss) from Associates and Joint Venture: Stood at Rs 436.19 crore in Q2FY27, up 20.47% QoQ compared to Rs 362.07 crore in Q1FY27 and up 124.27% YoY compared to Rs 194.49 crore in Q2FY26. Profit Attributable to Owners: Profit for the period attributable to equity holders of the company stood at Rs 441.48 crore in Q2FY27, rising 20.10% QoQ from Rs 367.60 crore in Q1FY27 and 126.43% YoY from Rs 194.97 crore in Q2FY26. Total Comprehensive Income: Recorded at Rs 433.85 crore in Q2FY27, growing 20.56% QoQ from Rs 359.86 crore in Q1FY27 and 129.77% YoY from Rs 188.82 crore in Q2FY26. Total comprehensive income attributable to equity holders of the company stood at Rs 439.14 crore in Q2FY27 compared to Rs 365.39 crore in Q1FY27 and Rs 189.30 crore in Q2FY26. Earnings Per Share (EPS): Basic EPS stood at Rs 8.17 per share in Q2FY27, up 19.97% QoQ from Rs 6.81 per share in Q1FY27 and up 126.32% YoY from Rs 3.61 per share in Q2FY26. Diluted EPS stood at Rs 8.16 per share in Q2FY27, up 20.00% QoQ from Rs 6.80 per share in Q1FY27 and up 126.04% YoY from Rs 3.61 per share in Q2FY26. Standalone Financial Highlights: Revenue from Operations: Stood at Rs 2,014.11 crore in Q2FY27, registering an increase of 14.62% QoQ from Rs 1,757.16 crore in Q1FY27 and an increase of 28.57% YoY from Rs 1,566.60 crore in Q2FY26. Other Income: Stood at Rs 24.72 crore in Q2FY27, up 23.17% QoQ compared to Rs 20.07 crore in Q1FY27, while down 13.11% YoY compared to Rs 28.45 crore in Q2FY26. Total Income: Recorded at Rs 2,038.83 crore in Q2FY27, an increase of 14.72% QoQ from Rs 1,777.23 crore in Q1FY27 and an increase of 27.82% YoY from Rs 1,595.05 crore in Q2FY26. Profit Before Tax: Reached Rs 519.62 crore in Q2FY27, up 33.86% QoQ compared to Rs 388.17 crore in Q1FY27 and up 79.90% YoY compared to Rs 288.84 crore in Q2FY26. Net Profit After Tax: Stood at Rs 388.13 crore in Q2FY27, representing a growth of 33.86% QoQ from Rs 289.96 crore in Q1FY27 and a growth of 79.96% YoY from Rs 215.67 crore in Q2FY26. Total Comprehensive Income: Stood at Rs 386.32 crore in Q2FY27, increasing 34.07% QoQ from Rs 288.15 crore in Q1FY27 and increasing 79.28% YoY from Rs 215.48 crore in Q2FY26. Earnings Per Share (EPS): Basic EPS was Rs 7.18 per share in Q2FY27, compared to Rs 5.37 per share in Q1FY27 (up 33.71% QoQ) and Rs 3.99 per share in Q2FY26 (up 79.95% YoY). Diluted EPS was Rs 7.18 per share in Q2FY27, compared to Rs 5.36 per share in Q1FY27 (up 33.96% QoQ) and Rs 3.99 per share in Q2FY26 (up 79.95% YoY). Business Highlights: Interim Dividend: The Board of Directors declared an Interim Dividend of Re 1.00 (i.e., 50%) per equity share of face value of Rs 2/- each for FY27. The record date is set as November 6, 2026, with the payment to be made on or after November 19, 2026. Scheme of Amalgamation and Demerger: The proposed Composite Scheme of Arrangement for the demerger of the Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and the amalgamation of the Remaining Undertaking of Laurus Synthesis Private Limited with the Company has been filed with the Hon'ble NCLT, Amaravati Bench, and remains pending regulatory approvals. The appointed date is April 01, 2026. Joint Venture Updates: The capital contribution of Rs 49 crore was made into KRKA Pharma Private Limited for a 49% stake, which is accounted for as a joint venture. Subsidiary Updates: Step-down subsidiary Laurus Generics GmbH has filed for liquidation during the quarter, with the process ongoing subject to a statutory one-year creditor objection period ending August 2027. Wholly owned subsidiary Laurus Specialty Chemicals Private Limited has not yet commenced commercial operations. Executive Appointments: Approved the appointment of Mr. Kundan Kumar Jha as Joint Company Secretary (Key Managerial Personnel) with effect from November 1, 2026. Result PDF
PDF
29 Oct 2026
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please see enclosed annexure
PDF
VIEW ALL

Laurus Labs DocumentsAsk MarketMind AI

Laurus Labs Earnings Call

Laurus Labs earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
30 Jul 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
24 Jul 2026Laurus Labs Results Earnings Call for Q1FY27AudioVideo
05 May 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
30 Apr 2026Laurus Labs Results Earnings Call for Q4FY26 & Full YearAudioVideo
28 Jan 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Laurus Labs Annual Reports

Laurus Labs financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Laurus Labs Credit Ratings

Laurus Labs credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
02 Jul 2026care ratingsLaurus Labs LimitedLink
30 Jun 2025care ratingsLaurus Labs LimitedLink
19 Jun 2024care ratingsLaurus Labs LimitedLink
22 Jun 2022care ratingsLaurus Labs LimitedLink
23 Jun 2021care ratingsLaurus Labs LimitedLink

Laurus Labs Investor Presentations

Laurus Labs investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
29 Oct 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
18 Sep 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
24 Jul 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Apr 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
23 Jan 2026Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Laurus Labs - Company Profile

Laurus Labs Management Structure

Laurus Labs management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
CHAVA SATYANARAYANAExecutive Director,Chief Executive Officer2480Mar 26
VENKATA RAVI KUMAR VANTARAMExecutive Director,Chief Financial Officer660Mar 26
Mr. Jyothi Basu AbbineniExecutive Vice President(R & D (Chemicals))-Mar 26
Mr. Girish KSenior Vice President - Operations(Operations)-Mar 26
Dr. Parkash SomSenior Vice President(Regulatory Affairs)-Mar 26
Dr. Ravindra Babu BSenior Vice President(R & D (Chemicals))-Mar 26
Mr. Giridhar MSenior Vice President(Quality Assurance)-Mar 26
Dr. Thilek Kumar MuniyappanSenior Vice President(R & D (Formulations))-Mar 26
Mr. Sumeet SobtiSenior Vice President(Supply Chain Management)-Mar 26
Mr. N BabchandExecutive Vice President(Business Development)-Mar 26
Mr. Ch. Venkata Ramana RaoExecutive Vice President(Intellectual Property,Management Development)-Mar 26
Venkateswar Reddy GogireddyCompany Secretary,Compliance Officer,Vice President(Legal.)-Mar 26
Mr. Arnaud MartinExecutive Vice President,Head(Business Development,CDMO)-Mar 26
Dr. Rajaram IyerExecutive Vice President(Portfolio Management Services)-Mar 26
Mr. Martyn Oliver James PeckExecutive Vice President(Business Development)-Mar 26
Mr. Thomas VersoskyPresident-Mar 26
Mr. Narasimha Rao ChavaExecutive Vice President(Human Resources)-Mar 26
Mr. S Srinivas RaoExecutive Vice President(Manufacturing)-Mar 26
Mr. Ch. Sita RamaiahExecutive Vice President(Finance)-Mar 26
Dr. Suresh PodaPresident(Drug Development & Research (Biologicals))-Mar 26
Mr. Srinivasa Rao SPresident(Manufacturing.,Operations)-Mar 26
Dr. V Uma Maheswer RaoPresident(Chemical.,R & D)-Mar 26

Laurus Labs Board of Directors

Laurus Labs Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
CHAVA SATYANARAYANAExecutive Director & CEO2480Mar 26
VENKATA RAVI KUMAR VANTARAMExecutive Director & CFO660Mar 26
Venkata Lakshmana Rao ChunduruExecutive Director456Mar 26
KRISHNA CHAITANYA CHAVAExecutive Director220Mar 26
Soumya ChavaExecutive Director135Mar 26
Rajesh Koshy ChandyIndependent Non Exe. Director46Mar 26
Ramesh SubrahmanianIndependent Non Exe. Director30Mar 26
Karnam SekarIndependent Non Exe. Director27Mar 26
Ravindranath KancherlaChairman & Independent Directo26Mar 26
Sutapa BanerjeeIndependent Director-Mar 26
Shekhar Chintamani MandeIndependent Director-Mar 26
Kundan Kumar JhaCompany Secretary / Compliance Officer-Mar 26
Website: www.lauruslabs.com

About the company - Business Profile

Laurus Labs Ltd. is a research-driven, integrated pharmaceutical company with a leadership position in the global generic market, particularly in high-potency Active Pharmaceutical Ingredients (APIs) and antiretroviral (ARV) therapies. The company operates through four primary business segments: Generics API, Generics Finished Dosage Forms (FDF), Synthesis (CDMO), and Biotechnology. Laurus Labs serves a diverse range of industries including human and animal health, crop science, and specialty ingredients. The company has established itself as a preferred partner for global innovator and generic pharmaceutical firms, leveraging its large-scale manufacturing capabilities and focus on complex chemistry.

Key Points

  • Key Facts:
    • Founded: 2005 (Corporate Identification No: L24239AP2005PLC047518).
    • Headquarters: Hyderabad, India.
    • Stock Listing: Listed on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
    • Key Products: Antiretrovirals (ARV), oncology, steroids, hormones, cardiovascular APIs, and oral solid formulations.
  • Operations and Resources:
    • Facilities: Operates 15 facilities approved by global regulators including the USFDA, WHO, EMA, and Japan PMDA.
    • Capacity: Total reactor volume exceeds 7,800 KL as of FY2025. The FDF segment has a capacity of 10 billion tablets/capsules per annum.
    • R&D: Operates 300+ labs in India with a dedicated R&D spend of ₹206 crore (4.1% of revenues) in 9M-FY2026.
  • Revenue Breakdown (FY2025):
    • Total Revenue: ₹5,554 crore.
    • Generics (API & FDF): ₹4,020 crore (72% of total revenue).
    • Synthesis (CDMO): ₹1,374 crore (25% of total revenue).
    • Biotechnology: ₹160 crore (3% of total revenue).
    • Geographical Mix (FY2024): Exports contribute 61% of revenue, with North America (17%), Europe (27%), and Rest of World (56%).
  • Market Significance and Business Model:
    • Laurus Labs is a leading third-party API supplier for antiretrovirals globally and possesses the largest High-Potent API capabilities in India.
    • The business model is built on vertical integration, where the company's API expertise supports its growing FDF business, enhancing cost-efficiency and supply chain reliability.
    • The Laurus Synthesis division provides custom manufacturing services to global pharma, crop science, and biotech firms.
  • Innovation and Strategic Initiatives:
    • Biotechnology: Through Laurus Bio, the company is expanding into microbial precision fermentation, serving sectors like regenerative medicine and vaccines.
    • Technology Platforms: Utilization of "Smart and Green" chemistry, trickle bed hydrogenation, spray drying, and continuous manufacturing processes.
    • Sustainability: Committed to near-term GHG targets under the Science Based Targets initiative (SBTi) and maintains an MSCI ESG rating of "BBB".
    • Future Outlook: Focus on scaling up the CDMO segment and complex generics. The company is investing in a $40 million fermentation-focused Capex for FY2025 to increase capacity in Mysore and Vizag.
  • Human Resources:
    • Employee Count: Total headcount of 7,042 as of FY2025.
    • The company has been certified as a Great Place to Work for six consecutive years (up to 2026).
    • Female employees represent 9% of the total workforce.
  • Financial Performance (9M-FY2026):
    • Revenue: ₹5,001 crore (30% YoY growth).
    • EBITDA Margin: 26.1% (an increase of 950 bps YoY).
    • Net Profit: ₹610 crore (388% YoY growth).
    • Net Debt-to-EBITDA: Reduced to 1.2x from 3.1x YoY.

References

  1. Investor Presentation Jan 2026
  2. Annual Report Apr 2025
  3. Investor Presentation Oct 2025
  4. Annual Report Apr 2024

Laurus Labs FAQ

Laurus Labs today is trading in the green, up by 7.2% at ₹2,405.5.
Laurus Labs is currently trading up 7.2% on an intraday basis. In the past week the stock rose 22.11%. Stock has been up 35.04% in the past quarter and rose 147.9% in the past year. You can view this in the share price history/seasonality section.
Laurus Labs is listed on NSE with the ticker LAURUSLABS and on BSE as 540222. It's currently trading on NSE at a share price of ₹2,405.5 and on BSE with a share price of ₹2,392.
The market cap of Laurus Labs is ₹129,972.1 Cr. as of Oct 30, 2026.
Laurus Labs announced a INTERIM dividend of 50% which equals ₹1 in Nov 06, 2026.The last three ex-dates for Laurus Labs were May 08, 2026, Oct 31, 2025 and May 09, 2025. To view the full dividend history of Laurus Labs click here.
Laurus Labs has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for Laurus Labs stock split was on Sep 29, 2020 at a ratio of 10:2.
Laurus Labs reported ₹2,219.38 Cr. in revenue, ₹441.48 Cr. in net profit, and ₹763.31 Cr. in EBITD as of Oct 29, 2026 for Q2 FY26-27.
According to the predictions of 14 analysts, the share price prediction for Laurus Labs is ₹1,753.43 with a downside of 27%.
The PE ratio of Laurus Labs is 97 as of Oct 30, 2026.
The PB ratio of Laurus Labs is 22.95 as of Oct 30, 2026.
You can view the latest analyst reports on the Laurus Labs reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×